ANGLE, a liquid biopsy company, said it has established a co-marketing agreement with QIAGEN, a provider of molecular testing solutions with more than 500,000 customers in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharma and biotech companies) and Academia (life sciences research).
The partnership will seek to leverage the advantages of combining ANGLE’s leading Parsortix system for harvesting circulating tumor cells (CTCs) with QIAGEN’s liquid biopsy solution portfolio which consists of dedicated NGS (next generation sequencing), PCR (polymerase chain reaction), single cell analysis products and bioinformatics capabilities. The initial focus will be on prostate and breast cancer research applications.
The agreement entails both companies offering the other’s products to its customer base and follows an intensive evaluation of Parsortix by QIAGEN identifying the advantages of the system.
“ANGLE’s Parsortix system is a unique, epitope-independent CTC solution offering easy, automated processing of whole blood to harvest all types of CTCs, including the clinically relevant mesenchymal CTCs, for analysis. It complements very well with our AdnaTest CTC portfolio, now allowing for both phenotypic and molecular characterization of CTCs. The modular combination abilities of this system with QIAGEN’s liquid biopsy-based Sample to Insight offering, including AdnaTest, our targeted RNAseq and single cell solutions, along with our bioinformatics offering, will allow scientists and clinical researchers to significantly advance their research,” said Michael Kazinski, QIAGEN’s Senior Director Molecular Preanalytic Technologies.
“We are delighted that Parsortix has been selected by QIAGEN as their label-free CTC harvesting technology. We believe the ability to offer customers a combination of Parsortix with validated and reliable downstream analysis technologies from a world leader such as QIAGEN facilitates key aspects of the sales cycle and we look forward to working closely together. Partnering is a core part of ANGLE’s strategy to secure widespread adoption of Parsortix right across the market leveraging the customer base and distribution channels of established players,” said ANGLE Founder and Chief Executive, Andrew Newland.
(This story has not been edited by Tech Observer staff and is auto-generated from a syndicated feed.)